Early Warning System

EIB-20240937 NEXT GENERATION AST (IEU TI HERA)



Quick Facts

Countries	Poland
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2025-08-05
Borrower	Bacteromic SP Z00
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 17.37 million
Project Cost (USD)	\$ 46.31 million



Project Description

According to the Bank's website, the project covers the Promoter's investments into the development of next generation antibiotic susceptibility testing technologies, including - inter alia - product enhancement, IP, regulatory approvals and market access.

The project aims to support the continued development and market access of BacterOMIC system - a diagnostic system for automatic antibiotic susceptibility testing (AST) which addresses the problem of increasing resistance of bacteria. As an automated system, it significantly simplifies and shortens laboratory procedures while analysing nearly all clinically relevant antibiotics to better determine the most effective treatment of bacterial infections.

Early Warning System Project Analysis

According to the Environmental and Social Data Sheet, the project concerns investments in research and development for which no significant impact on the environment is expected.

Investment Description

• European Investment Bank (EIB)

Private Actors Description

Bacteromic SP ZOO is a Polish medical technology company that is developing an automated antibiotic susceptibility testing system, with applications for use in hospitals and laboratories to determine the appropriate antibiotic for clinical care.





Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Bacteromic SP Z00	Client	-

Contact Information

No contacts available at the time of disclosure.

ACCESS TO INFORMATION

You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check:

http://www.eib.org/attachments/strategies/complaints mechanism policy en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces

Bank Documents

• 23/09/2025 - Environmental and Social Data Sheet (ESDS) - NEXT GENERATION AST (IEU TI HERA)

Other Related Projects

• EIB-20230791 THEMATIC INNOVATION (INVESTEU VD) LE II